Cancer company Neotropix Inc. raised $10 million in its first round of private equity financing. The funding is projected to carry the Malvern, Pa.-based company's lead product through Phase I/II trims in small-cell lung cancer. Labeled SVV-001, the product is Seneca Valley virus, or SVV. It has shown efficacy in murine …
No comments:
Post a Comment